scispace - formally typeset
K

Kevin M. Brindle

Researcher at University of Cambridge

Publications -  314
Citations -  22755

Kevin M. Brindle is an academic researcher from University of Cambridge. The author has contributed to research in topics: In vivo & Magnetic resonance imaging. The author has an hindex of 70, co-authored 296 publications receiving 19633 citations. Previous affiliations of Kevin M. Brindle include Laboratory of Molecular Biology & Cancer Research UK.

Papers
More filters
Journal ArticleDOI

A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations

TL;DR: It is demonstrated how the intracellular concentrations of metabolites can reveal phenotypes for proteins active in metabolic regulation, and this approach to functional analysis, using comparative metabolomics, is called FANCY—an abbreviation for functional analysis by co-responses in yeast.
Journal ArticleDOI

Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

TL;DR: In lymphoma-bearing mice injected intravenously with hyperpolarized [1-13C]pyruvate, it is shown that the lactate dehydrogenase–catalyzed flux of 13C label between the carboxyl groups of pyruvates and lactate in the tumor can be measured using 13C magnetic resonance spectroscopy and spectroscopic imaging, and that this flux is inhibited within 24 h of chemotherapy.
Journal ArticleDOI

Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate

TL;DR: Tissue pH can be imaged in vivo from the ratio of the signal intensities of hyperpolarized bicarbonate and 13CO2 following intravenous injection of hyperPolarized H13CO3-.
Journal ArticleDOI

Imaging biomarker roadmap for cancer studies.

James P B O'Connor, +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.